ClinicalTrials.gg
CompletedNCT04254978Updated May 4, 2026Results posted

Study of Bomedemstat in Participants With Essential Thrombocythemia (IMG-7289-CTP-201/MK-3543-003)

A Phase 2 interventional study of Bomedemstat in Essential Thrombocythemia, sponsored by Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA). Completed at 26 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-04.

Sponsored by Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA) (part of Merck & Co., Inc) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
73
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 149 studies in Thrombocythemia, Essential with a site in United States — 18 open to participants now, 32 under way, 6 of them phase 3. Thrombocythemia, Essential · United States.

Enrollment
43rd of 120
73 · median 45
Started
2020
with 5 others
Phase 2
49 of 149
6 open now
Registered
123rd of 149
by date

Among the 149 studies in Thrombocythemia, Essential with a site in United States, this one is the 43rd largest by enrollment of the 120 interventional ones that give a count, is one of 6 that started in 2020, is one of 49 in phase 2, and was the 123rd registered.

Thrombocythemia, Essential

229 studies on the registry are indexed under Thrombocythemia, Essential; 38 are open to participants now.

Browse Thrombocythemia, Essential studies →

Open to participants now

18 of the 149 studies in Thrombocythemia, Essential with a site in United States are open now. Recruiting first, the newest first:

13 more — sign in →

All 18 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 34 Thrombocythemia, Essential studies recruiting now, 30 (88%) set no upper age limit and 3 (9%) stop at 75 or younger; 5 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 149 studies in Thrombocythemia, Essential with a site in United States, or all of them as a file.
02

Study summary

This is a Phase 2b open label study of an orally administered LSD1 inhibitor, Bomedemstat (MK-3543, formerly called IMG-7289), in patients with essential thrombocythemia.

This study investigates the following:

  • The safety and tolerability of Bomedemstat
  • The pharmacodynamic effect of Bomedemstat
Read the detailed description

This is a Phase 2 multi-center, open-label study evaluating the safety, efficacy and pharmacodynamics of Bomedemstat administered orally once daily in patients with essential thrombocythemia (ET). Patients will be dosed with Bomedemstat for 169 consecutive days in the Initial Treatment Period (ITP). Qualifying patients may continue to receive Bomedemstat in the Additional Treatment Period (ATP).

Safety will be evaluated by clinical assessments of safety parameters i.e., safety laboratory testing, adverse event reporting, physical examination and vital sign assessments. Pharmacodynamics will be evaluated by hematology assessment, patient reported symptom burden, change in spleen size by palpation and other measures.

To ensure safety, a Safety Advisory Board will perform periodic reviews of safety parameters and pharmacodynamic markers.

03

Conditions studied

  • Essential Thrombocythemia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of Essential Thrombocythemia per World Health Organization (WHO) diagnostic criteria for myeloproliferative neoplasms.
  • Requires treatment in order to lower count based on patient age over 60 or history of thrombosis.
  • Have failed at least one standard therapy
  • Must have discontinued ET therapy at least 1 week (4 weeks for interferon) prior to study drug initiation.

Exclusion criteria

Exclusion Criteria:

  • Has undergone major surgery ≤4 weeks prior to starting study drug or has not recovered from side effects of such surgery.
  • Unresolved treatment related toxicities from prior therapies (unless resolved to ≤ Grade 1).
  • Uncontrolled active infection.
  • Current use of prohibited medications
  • Known infection or active or virus infection
  • Other hematologic/biochemistry requirements, as per protocol
  • Use of agent within last 14 days
  • Pregnant or lactating females
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
73 participants (actual)

Study arms

  • Experimental
    Bomedemstat

    Bomedemstat administered daily for 169 consecutive days

    Drug: Bomedemstat

Interventions

  • Oral administration

    Also known as: IMG-7289, MK-3543

06

What researchers measure

Primary outcomes

  1. Number of Participants Who Experienced an Adverse Event (AE)

    An AE is any undesirable physical, psychological or behavioral effect experienced by a participant during the study, in conjunction with the use of the drug or biologic, whether or not product related. This includes any untoward signs or symptoms experienced by the participant from the time of first dose with study treatment until completion of the study. The number of participants who experienced an AE is reported.

    Time frame: Up to approximately 30 months

  2. Number of Participants Who Discontinued Study Treatment Due to an AE

    An AE is any undesirable physical, psychological or behavioral effect experienced by a patient during participation in the study, in conjunction with the use of the drug or biologic, whether or not product-related. This includes any untoward signs or symptoms experienced by the patient from the time of first dose with study treatment until completion of the study. The number of participants who discontinued study treatment due to an AE is reported.

    Time frame: Up to approximately 28 months

  3. Percentage of Participants With Platelet Count ≤400 k/μL at Day 169

    Blood samples were collected at pre-specified timepoints to determine platelet counts. The percentage of participants who achieved reduction in platelet count to ≤400k/μL in the absence of new thrombolytic events is reported.

    Time frame: Up to day 169

07

Results

Posted Apr 2, 2024

Participant flow

Initial Treatment Period (ITP)
Participant flow — Initial Treatment Period (ITP)
MilestoneBomedemstat
Started73
Completed64
Not completed9
Withdrew: Withdrawal by subject3
Withdrew: Adverse event5
Withdrew: Lack of efficacy1
Additional Treatment Period (ATP)
Participant flow — Additional Treatment Period (ATP)
MilestoneBomedemstat
Started63
Completed52
Not completed11
Withdrew: Withdrawal by subject3
Withdrew: Physician decision1
Withdrew: Adverse event7

Outcome measures

PrimaryNumber of Participants Who Experienced an Adverse Event (AE)

An AE is any undesirable physical, psychological or behavioral effect experienced by a participant during the study, in conjunction with the use of the drug or biologic, whether or not product related. This includes any untoward signs or symptoms experienced by the participant from the time of first dose with study treatment until completion of the study. The number of participants who experienced an AE is reported.

Time frame:
Up to approximately 30 months
Reported as:
Count of participants · Participants
Number of Participants Who Experienced an Adverse Event (AE)
ParticipantsBomedemstat
Number of Participants Who Experienced an Adverse Event (AE)73
PrimaryNumber of Participants Who Discontinued Study Treatment Due to an AE

An AE is any undesirable physical, psychological or behavioral effect experienced by a patient during participation in the study, in conjunction with the use of the drug or biologic, whether or not product-related. This includes any untoward signs or symptoms experienced by the patient from the time of first dose with study treatment until completion of the study. The number of participants who discontinued study treatment due to an AE is reported.

Time frame:
Up to approximately 28 months
Reported as:
Count of participants · Participants
Number of Participants Who Discontinued Study Treatment Due to an AE
ParticipantsBomedemstat
Number of Participants Who Discontinued Study Treatment Due to an AE11
PrimaryPercentage of Participants With Platelet Count ≤400 k/μL at Day 169

Blood samples were collected at pre-specified timepoints to determine platelet counts. The percentage of participants who achieved reduction in platelet count to ≤400k/μL in the absence of new thrombolytic events is reported.

Time frame:
Up to day 169
Reported as:
Number · Percentage of Participants
Percentage of Participants With Platelet Count ≤400 k/μL at Day 169
Percentage of ParticipantsBomedemstat
Percentage of Participants With Platelet Count ≤400 k/μL at Day 16976.6 (64.3 to 86.2)
Statistical analysis
  • Bomedemstat · Exact binomial distribution · p = <.0001

Adverse events

Collected over Up to approximately 30 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Bomedemstat2/73 (2.7%)27/73 (37%)72/73 (98.6%)
Most frequent serious events
Showing 10 of 41
Most frequent serious events
EventBomedemstat
ThrombocytopeniaBlood and lymphatic system disorders4/73
PneumoniaInfections and infestations3/73
Gastrointestinal haemorrhageGastrointestinal disorders2/73
DiverticulitisInfections and infestations2/73
ContusionInjury, poisoning and procedural complications2/73
ArthralgiaMusculoskeletal and connective tissue disorders2/73
AnemiaBlood and lymphatic system disorders1/73
Atrial fibrillationCardiac disorders1/73
Cardiac failureCardiac disorders1/73
Abdominal painGastrointestinal disorders1/73
Most frequent other events
Showing 10 of 56
Most frequent other events
EventBomedemstat
DysgeusiaNervous system disorders43/73
ConstipationGastrointestinal disorders29/73
ArthralgiaMusculoskeletal and connective tissue disorders29/73
ThrombocytopeniaBlood and lymphatic system disorders23/73
FatigueGeneral disorders21/73
COVID-19Infections and infestations19/73
ContusionInjury, poisoning and procedural complications18/73
DiarrhoeaGastrointestinal disorders15/73
AnaemiaBlood and lymphatic system disorders14/73
AlopeciaSkin and subcutaneous tissue disorders14/73

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Bomedemstat
Mean64.8 ± 10.40
Sex: Female, Male
Sex: Female, Male(Participants)Bomedemstat
Female42
Male31
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Bomedemstat
Hispanic or Latino1
Not Hispanic or Latino71
Unknown or Not Reported1
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Bomedemstat
American Indian or Alaska Native0
Asian18
Native Hawaiian or Other Pacific Islander0
Black or African American3
White51
More than one race0
Unknown or not reported0
Aboriginal1
08

Study locations

26 sites
  • Local Institution
    Jacksonville, Florida 32209, United States
  • Local Institution
    Ann Arbor, Michigan 48109, United States
  • Local Institution
    New York, New York 10021, United States
  • Local Institution
    Durham, North Carolina 27710, United States
  • Cleveland Clinic
    Cleveland, Ohio 44195, United States
  • Local Institution
    Pittsburgh, Pennsylvania 15232, United States
  • Local Institution
    Seattle, Washington 98109, United States
  • Local Institution
    Herston, Brisbane, Australia
  • Local Institution
    Camperdown, New South Wales, Australia
  • Local Institution
    St Leonards, New South Wales 2065, Australia
  • Local Institution
    Southport, Queensland, Australia
  • Royal Adelaide Hospital
    Adelaide, South Australia 5000, Australia
  • Local Institution
    Clayton, Victoria 3168, Australia
  • Department of Hematology and Stem Cell Transplantation, West German Cancer Center (WTZ)
    Essen, 45147, Germany
  • Local Institution
    Jena, Germany
  • Local Institution
    Hong Kong, Hong Kong
  • Local Institution
    Alessandria, Italy
  • Local Institution
    Bologna, Italy
  • CRIMM; Centro Ricerca e Innovazione delle Malattia Mieloproliferative, Azienda ospedaliera Universitaria Careggi
    Florence, 50139, Italy
  • Local Institution
    Varese, Italy
  • Local Institution
    Auckland, New Zealand
  • Middlemore Hospital
    Auckland, New Zealand
  • Local Institution
    London, NW1, United Kingdom
  • Guys and St Thomas Hospital
    London, SE1 9RT, United Kingdom
  • Local Institution
    London, W12, United Kingdom
  • Local Institution
    Oxford, United Kingdom
09

References and documents

Publications

  • Gill H, Palandri F, Ross DM, Gothert JR, Cochrane T, Larsen SR, Halpern AB, Shortt J, Rossetti JM, Liang J, Marchetti M, Wilson AJ, Innes AJ, Hanna M, Vianelli N, Stevenson WS, Vannucchi AM, Kleppe M, Flynn J, Natsoulis G, Harrison CN, Rienhoff HY Jr. Phase 2 study of the lysine-specific demethylase 1 inhibitor bomedemstat for essential thrombocythemia. Blood Adv. 2026 May 26;10(10):3494-3504. doi: 10.1182/bloodadvances.2025017575. PubMed 41758981 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2020 to primary completion in Mar 2023, 30 months.

Results were first posted in Apr 2024, 1 year after primary completion.

Of 27 phase 2 interventional studies under Thrombocythemia, Essential, half reached primary completion within 64 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 141. This study's 30 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 15, 2020
First posted
Feb 5, 2020
StartActual
Sep 8, 2020
Primary completionActual
Mar 23, 2023
CompletionActual
Mar 23, 2023
Results first posted
Apr 2, 2024
Last update
May 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04254978
Responsible party
Sponsor
First posted
Feb 5, 2020
Start date
Sep 8, 2020
Primary completion
Mar 23, 2023
Completion
Mar 23, 2023
Results posted
Apr 2, 2024
Last update
May 4, 2026

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bomedemstat

Start the discussion